COMPANY PROFILE

Imidomics

Explore full profile

Focuses on developing new medicines for immune-mediated inflammatory diseases

San Rafael, United StatesFounded 2015Biotech & Life Sciences

Valuation $50–100M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Imidomics

IMIDomics is a pioneering biotechnology company focused on developing innovative therapies for immune-mediated inflammatory diseases (IMIDs). Leveraging 17 years of data and sample collection, the company collaborates with 130 recruiting centers and 300 investigators across Spain and Paraguay. IMIDomics targets debilitating diseases such as Systemic Lupus Erythematosus, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Atopic Dermatitis. The company operates in the biopharmaceutical market, serving patients who fail to respond or develop resistance to current treatments. Its business model revolves around the development of first-in-class medicines, driven by a patient-first ethos. Revenue is generated through the commercialization of these novel therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: San Rafael, United States
Employees: 26
Open positions: None listed
Dealroom signal: 59.5/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Mar 2024	$0	—	UCB	↗
OtherOther financing	Feb 2022	$0	—	Evotec	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Imidomics website traffic

Latest recorded traffic for Imidomics is 1K monthly website visits, up 17.6% over the last three months. Imidomics's team declined 10.3% over the past year.

Latest monthly visits1K 3-month web change+17.6% 1-year team growth-10.3%

Monthly website visitsJan 2021–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STSimcha TherapeuticsDeveloping engineered cytokine immunotherapy for cancer	New Haven, United States	Operational	8	$65M	$160M
QRQritiveAI-powered clinical decision support for cancer diagnosis	Singapore, Singapore	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
ELEpigene LabsHelping cancer researchers develop new treatments and drugs by providing them with data-driven insights	Paris, France	Operational
STSynendos TherapeuticsDeveloped first-in-class endocannabinoid modulators to restore natural functioning of the brain in CNS disorders	Basel, Switzerland	Operational
GHGeneQuantum HealthcareGeneQuantum Healthcare is a high-tech company that focuses on the research and development of innovative Bio-therapeutics	Dongcheng District, China	Operational
PRPredxBioTissue-Based Decision Intelligence for Oncology	Bellevue, United States	Operational
RERevrFormerly Tierra Biosciences. Accelerates bio-discovery using cell-free systems combined with powerful automation tools for data generation	San Leandro, United States	Operational